Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) Non Operating Investment Income (2018 - 2025)

Historic Non Operating Investment Income for Lexaria Bioscience (LEXX) over the last 8 years, with Q4 2025 value amounting to -$22093.0.

  • Lexaria Bioscience's Non Operating Investment Income fell 3867.06% to -$22093.0 in Q4 2025 from the same period last year, while for Nov 2025 it was -$39875.0, marking a year-over-year decrease of 2249.63%. This contributed to the annual value of -$33714.0 for FY2025, which is 5172.33% up from last year.
  • Lexaria Bioscience's Non Operating Investment Income amounted to -$22093.0 in Q4 2025, which was down 3867.06% from -$11447.0 recorded in Q3 2025.
  • In the past 5 years, Lexaria Bioscience's Non Operating Investment Income ranged from a high of $34040.0 in Q1 2025 and a low of -$143918.0 during Q3 2023
  • Moreover, its 5-year median value for Non Operating Investment Income was -$19012.5 (2024), whereas its average is -$27764.1.
  • Its Non Operating Investment Income has fluctuated over the past 5 years, first tumbled by 430773.14% in 2021, then skyrocketed by 86250.62% in 2024.
  • Over the past 5 years, Lexaria Bioscience's Non Operating Investment Income (Quarter) stood at -$41362.0 in 2021, then plummeted by 87.68% to -$77628.0 in 2022, then surged by 31.45% to -$53215.0 in 2023, then skyrocketed by 70.06% to -$15932.0 in 2024, then plummeted by 38.67% to -$22093.0 in 2025.
  • Its Non Operating Investment Income was -$22093.0 in Q4 2025, compared to -$11447.0 in Q3 2025 and -$40375.0 in Q2 2025.